SEARCH

SEARCH BY CITATION

References

  • 1
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558567.
  • 2
    Van Ameijden EJ, Coutinho RA. measures targeted at injecting drug users. AIDS 1998; 12: 625633.
  • 3
    Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212220.
  • 4
    Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001; 165: 889895.
  • 5
    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383398, vi.
  • 6
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 7
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 8
    Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005; 25: 1832.
  • 9
    Grebely J, Raffa J, Meagher C, Duncan F, Viljoen M, Khara M, et al. Treatment of hepatitis C virus infection in previous and current injection drug users. In: Programs and Abstracts of the 17th International Conference on the Reduction of Drug Related Harm; Vancouver, British Columbia, Canada, 2006.
  • 10
    Proust B, Dubois F, Bacq Y, Le Pogam S, Rogez S, Levillain R, et al. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 2000; 38: 31253127.
  • 11
    Micallef JM, Jauncey M, Amin J, Rawlinson W, Gilmour S, van Beek I, et al. Hepatitis C virus re-infection within a cohort of injecting drug users [Abstract 229]. HEPATOLOGY 2003; 38: 266A.
  • 12
    Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388390.
  • 13
    Tisone G, Baiocchi L, Orlando G, Palmieri GP, Pisani F, Rapicetta M, et al. Hepatitis C reinfection after liver transplantation in relation to virus genotype. Transplant Proc 1999; 31: 490491.
  • 14
    Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135140.
  • 15
    Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003; 77: 47814793.
  • 16
    Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004; 78: 15751581.
  • 17
    Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 16451655.
  • 18
    Wyatt CA, Andrus L, Brotman B, Huang F, Lee DH, Prince AM. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol 1998; 72: 17251730.
  • 19
    Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 14781483.
  • 20
    Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36: S35S46.
  • 21
    Kim A, Schulze Zur Wiesch J, Allen T, Gandhi R, Davis B, Jones A, et al. Virus-specific T-cell responses and loss of spontaneous control of HCV in HIV+ individuals. 13th Conference on Retroviruses and Opportunistic Infections 2006:Abstract_84.
  • 22
    Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659662.
  • 23
    Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. HEPATOLOGY 2001; 33: 14791487.
  • 24
    Weseslindtner L, Aberle JH, Gurguta C, Steindl-Munda P, Popow-Kraupp T, Ferenci P, et al. Reinfection with the hepatitis C virus: kinetics of viral clearance and multi-parameter analysis of CD4+ T-cell response [Abstract 447]. J Hepatol 2006; 44: S167.
  • 25
    Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL. Viral evolution of hepatitis C in injection drug users. J Viral Hepat 2005; 12: 574583.
  • 26
    Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 1621.
  • 27
    Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 47924797.
  • 28
    Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872874.
  • 29
    Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 15401543.
  • 30
    Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40( Suppl 5): S336S338.